Published in Antimicrob Agents Chemother on April 01, 2003
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2004) 1.34
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 1.25
Coding tandem repeats generate diversity in Aspergillus fumigatus genes. Eukaryot Cell (2007) 1.23
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother (2004) 1.21
In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother (2008) 1.01
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother (2003) 0.98
In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother (2006) 0.92
New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol (2003) 0.84
In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2004) 0.84
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother (2012) 0.82
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother (2009) 0.80
Combinatorial strategies for combating invasive fungal infections. Virulence (2016) 0.80
Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions. Antimicrob Agents Chemother (2013) 0.79
Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother (2007) 0.78
In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies. Antimicrob Agents Chemother (2013) 0.75
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2001) 3.28
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother (2002) 2.26
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob Agents Chemother (1989) 1.53
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs (2001) 1.48
Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect (2002) 1.16
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Isr Med Assoc J (2005) 1.82
Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2010) 1.71
Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J (2008) 1.65
Listeria monocytogenes infection in Israel and review of cases worldwide. Emerg Infect Dis (2002) 1.58
Secondary bacteremia after rotavirus gastroenteritis in infancy. Pediatrics (2006) 1.58
Infective endocarditis in diabetic and non-diabetic patients. Scand J Infect Dis (2004) 1.42
Oral amphotericin B for the prevention of Candida bloodstream infection in critically ill children. Pediatr Crit Care Med (2006) 1.42
Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother (2003) 1.41
Association of Helicobacter pylori with coronary artery disease and myocardial infarction assessed by myocardial perfusion imaging. Isr Med Assoc J (2014) 1.40
Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2004) 1.34
Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 1.33
Coding tandem repeats generate diversity in Aspergillus fumigatus genes. Eukaryot Cell (2007) 1.23
Chlorhexidine-impregnated dressing for prevention of colonization of central venous catheters in infants and children: a randomized controlled study. Pediatr Infect Dis J (2005) 1.11
Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis (2006) 1.09
Disruption of the Aspergillus fumigatus ECM33 homologue results in rapid conidial germination, antifungal resistance and hypervirulence. Microbiology (2006) 1.08
Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. Clin Microbiol Infect (1995) 1.03
Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis (2008) 1.01
Infectious complications of peripherally inserted central venous catheters in children. Pediatr Infect Dis J (2010) 1.01
Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis (2003) 1.01
Involvement of secreted Aspergillus fumigatus proteases in disruption of the actin fiber cytoskeleton and loss of focal adhesion sites in infected A549 lung pneumocytes. J Infect Dis (2004) 1.01
Invasive Kingella kingae infections in children: clinical and laboratory characteristics. Pediatrics (2008) 1.00
Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. Respir Med (2008) 0.98
Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol (2007) 0.96
Susceptibility of Helicobacter pylori isolates to the antiadhesion activity of a high-molecular-weight constituent of cranberry. Diagn Microbiol Infect Dis (2004) 0.95
Transcription factor PrtT controls expression of multiple secreted proteases in the human pathogenic mold Aspergillus fumigatus. Infect Immun (2009) 0.95
The Aspergillus nidulans pkcA gene is involved in polarized growth, morphogenesis and maintenance of cell wall integrity. Curr Genet (2007) 0.94
Catheter-associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol (2006) 0.94
Prevalence and risk factors for herpes simplex virus type 2 infection among pregnant women in Israel. Sex Transm Dis (2003) 0.93
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother (2002) 0.93
First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis (2007) 0.92
Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine (2004) 0.91
Vaginitis in a gynecologic practice in Israel: causes and risk factors. Isr Med Assoc J (2003) 0.91
Anti-inflammatory effects of moxifloxacin on IL-8, IL-1beta and TNF-alpha secretion and NFkappaB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemother (2005) 0.91
The Aspergillus fumigatus cspA gene encoding a repeat-rich cell wall protein is important for normal conidial cell wall architecture and interaction with host cells. Eukaryot Cell (2010) 0.91
Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother (2010) 0.91
Efficacy of allicin, the reactive molecule of garlic, in inhibiting Aspergillus spp. in vitro, and in a murine model of disseminated aspergillosis. J Antimicrob Chemother (2004) 0.90
Hospitalizations for nosocomial rotavirus gastroenteritis in a tertiary pediatric center: a 4-year prospective study. Am J Infect Control (2009) 0.90
The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J (2007) 0.88
PrtT-regulated proteins secreted by Aspergillus fumigatus activate MAPK signaling in exposed A549 lung cells leading to necrotic cell death. PLoS One (2011) 0.88
Analysis of the Aspergillus nidulans thaumatin-like cetA gene and evidence for transcriptional repression of pyr4 expression in the cetA-disrupted strain. Fungal Genet Biol (2005) 0.87
Disruption of the Aspergillus fumigatus argB gene using a novel in vitro transposon-based mutagenesis approach. Curr Genet (2004) 0.87
Identification of novel cell wall destabilizing antifungal compounds using a conditional Aspergillus nidulans protein kinase C mutant. J Antimicrob Chemother (2009) 0.86
Unusual "flesh-eating" strains of Escherichia coli. J Clin Microbiol (2012) 0.85
Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrin and amphotericin B. Antimicrob Agents Chemother (2011) 0.85
Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol (2003) 0.84
Trivalent ultrashort lipopeptides are potent pH dependent antifungal agents. J Med Chem (2012) 0.84
Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor. Mol Nutr Food Res (2007) 0.84
In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2004) 0.84
Elevated 13C urea breath test values females infected with Helicobacter pylori. Dig Dis Sci (2007) 0.84
Cryptosporidiosis in children following solid organ transplantation. Pediatr Infect Dis J (2012) 0.83
Adenovirus infection in hospitalized immunocompetent children. Clin Pediatr (Phila) (2004) 0.82
The Aspergillus nidulans cetA and calA genes are involved in conidial germination and cell wall morphogenesis. Fungal Genet Biol (2007) 0.81
Association of Helicobacter pylori infection with Shigella gastroenteritis in young children. Am J Gastroenterol (2004) 0.81
Association of CagA+ Helicobacter pylori infection with aortic atheroma. Atherosclerosis (2004) 0.81
In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis (2006) 0.81
Use of the Porcine Intestinal Epithelium (PIE)-Assay to analyze early stages of colonization by the human fungal pathogen Candida albicans. J Basic Microbiol (2006) 0.81
Penicillin and ceftriaxone susceptibility of Streptococcus pneumoniae isolated from cerebrospinal fluid of children with meningitis hospitalized in a tertiary hospital in Israel. Isr Med Assoc J (2010) 0.81
Soluble triggering receptor expressed on myeloid cells-1 for diagnosing empyema. Ann Thorac Surg (2009) 0.80
Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci (2006) 0.80
Adult calcific aortic stenosis and Chlamydia pneumoniae: the role of Chlamydia infection in valvular calcification. Isr Med Assoc J (2006) 0.80
Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci (2006) 0.80
Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia. Int J Infect Dis (2012) 0.79
Alcohol-mediated haemolysis in yeast. Yeast (2004) 0.79
Clinical, laboratory, and microbiological differences between children with simple or complicated mastoiditis. Int J Pediatr Otorhinolaryngol (2009) 0.79
Transcriptional and proteomic analysis of the Aspergillus fumigatus ΔprtT protease-deficient mutant. PLoS One (2012) 0.79
Antibiotic resistance of Helicobacter pylori in Israeli children. Scand J Gastroenterol (2010) 0.79
Ecthyma gangrenosum caused by disseminated Exserohilum in a child with leukemia: a case report and review of the literature. Pediatr Dermatol (2003) 0.79
Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect (2008) 0.79
Predictors for anaerobic bacteraemia beyond the source of infection: retrospective, nested, case-control study. Scand J Infect Dis (2009) 0.78
Non-Escherichia coli versus Escherichia coli community-acquired urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and outcome. Pediatr Infect Dis J (2005) 0.78
Seven-year study of bacteremia in hospitalized patients on chronic hemodialysis in a single tertiary hospital. Ren Fail (2003) 0.78
Alcohol-conferred hemolysis in yeast is a consequence of increased respiratory burden. FEMS Yeast Res (2007) 0.77
Community-associated methicillin-resistant Staphylococcus aureus infections in Israel. Isr Med Assoc J (2010) 0.77
Molecular epidemiology of clostridium difficile in a tertiary medical center in Israel: emergence of the polymerase chain reaction ribotype 027. Isr Med Assoc J (2011) 0.77
Community-acquired enterococcal urinary tract infections in hospitalized children. Pediatr Nephrol (2011) 0.77
In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol (2009) 0.77
Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. Antimicrob Agents Chemother (2009) 0.77
Efficacy of subcutaneous tunneling for prevention of bacterial colonization of femoral central venous catheters in critically ill children. Pediatr Infect Dis J (2002) 0.76
Novel Water-Soluble Amphotericin B-PEG Conjugates with Low Toxicity and Potent in Vivo Efficacy. J Med Chem (2016) 0.75
Ill from eel? Lancet Infect Dis (2003) 0.75
Correction: Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target. PLoS Pathog (2016) 0.75
Infective endocarditis in previously healthy children with structurally normal hearts. Pediatr Cardiol (2013) 0.75
Aspergillus fumigatus Copper Export Machinery and Reactive Oxygen Intermediate Defense Counter Host Copper-Mediated Oxidative Antimicrobial Offense. Cell Rep (2017) 0.75
Host-Fungal Interactions: Pathogenicity versus Immunity. Int J Microbiol (2012) 0.75
Inducible clindamycin resistance among methicillin-sensitive Staphylococcus aureus infections in pediatric patients. Isr Med Assoc J (2011) 0.75
Thick fits Fitz. Lancet Infect Dis (2005) 0.75